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Abstract
We describe the case of a childbearing-age woman presenting with spontaneous recurrent functional ovarian
cysts and, more interestingly, chronic and asymptomatic elevation of cholestatic parameters. The patient
showed no history of chronic viral infections, immunological and metabolic disorders, alcohol abuse and
environmental toxins exposition. Hepatic ultrasonography and cholangio-pancreatography-magnetic-
resonance excluded any morphological and structural abnormalities, while liver biopsy evidenced only mini-
mal and not speciﬁc features of inﬂammation. Cholestasis indices obtained prompt recovery after each cycle
of synthetic hormone therapy, implanted to treat functional ovarian cysts. She has continuously experienced
the off-therapy asynchronous recurrence of liver laboratory abnormalities and functional ovarian cysts. The
favorable effect of the synthetic hormone therapy to obtaining a stable recovery of this unexplained long-
lasting cholestatic syndrome could be likely explained by downregulation of an endogenous ovarian overpro-
duction, although estrogen-regulated local intracellular transduction pathways cannot be excluded.
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Introduction
Functional ovarian cysts (FOC) are benign and gener-
ally asymptomatic disorders, with an occurrence in
about 7% of asymptomatic childbearing-age women
and an occasional discovery varying from 14% to 18%
in postmenopausal women.1,2 FOC can occur during
the ovarian hyperstimulation syndrome (OHSS), as
complication of ovarian stimulation to induce preg-
nancy; in OHSS setting, FOC cause overproduction of
ovarian hormones, such as oestrogens and progester-
one, potentially determining liver damage.3 In addition,
synthetic hormone therapy (SHT), widely used to treat
several gynecological disorders, is a well-known risk
factor for drug-induced liver injury, determining in
animal models marked congestion blood vessels, dis-
tended sinusoids with dilated central veins as well as
degeneration, necrosis of hepatocytes and distinct ﬁbro-
sis.4 In this paper, we reported the case of a young, lean
woman presenting with experienced history of liver
biochemical alterations, mostly including cholestasis
abnormalities, and recurrent FOC, both responsive to
SHT and off-therapy relapsing. Her FOC were sponta-
neous and not associated with OHSS. This cholestatic
syndromewas asymptomatic and showed a poor beneﬁt
from ursodesossicholic acid (UDCA) therapy. SHT was
prolonged to suppress the repeated FOC. We have
compared this case with scarce evidence from literature,
hypothesizing possible etio-pathogenetic mechanisms
and potential clinical implications.
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Case Report
On February 2009, an asymptomatic 28-year-old
woman presented with high serum aminotransferases
(prevalence of alanine aminotransferase [ALT],
1.6 × upper of normal limit [unl]) and cholestasis indi-
ces (gamma glutamyl transpeptidase [GGT], 6.6 × unl;
alkaline phosphatase [ALP], 1.9 × unl; direct bilirubin
was 0.40 mg/dL and total bilirubin was 1.46 mg/dL),
lasting since 2003 and discovered in occasion of a CMV
infection. A previous liver biopsy performed in 2004
evidenced only ‘minimal and not signiﬁcant alter-
ations’, such as small spots of intralobular inﬂamma-
tion and lipofuscin pigment occurrence in
centrolobular zone and in Kupffer cells. Markers of
hepatotropic viruses were repeatedly negative, as well
as antinuclear, antiextractable nuclear antigen, anti-
smooth muscle, antimitochondrial, antiliver-kidney
microsomal type 1, antineutrophil cytoplasmic, anti-
gliadin and antiendomysium antibodies. Patient did
not present with deﬁcit of alpha1 antitrypsin or cerulo-
plasmin and signs of iron overload. Personal informa-
tion did not reveal noticeable assumption of alcohol,
nor exposition to environmental or professional toxics.
BMI was stable around 21 with a waist circumference
between 72 and 74 cm. The age at menarche was
12 years, followed by regular menses. Familial history
evidenced biliary lithiasis, nonalcoholic fatty liver and
hepatocarcinoma. Previous treatment by UDCA at a
dosage of 15 mg/Kg/die/9 months ended up in no
signiﬁcant improvement.
On April 2009, a liver ultrasonography (US) fol-
lowed by a without intravenous contrast cholangio-
pancreatography-magnetic-resonance conﬁrmed the
absence of morphological and structural abnormali-
ties. A pelvic US, performed during a gynecological
screening, showed an ovarian cyst. Breasts at US
did not demonstrate any morpho-structural
alteration.
From December 2009 to December 2010, the patient
showed unexpected, rapid recovery of aminotransfer-
ases and cholestasis indices in occasion of the SHT
with chlormadinone acetate (2 mg)/ethinyl estradiol
(0.03 mg), scheduled for a 21-day cicle/month start-
ing from the ﬁrst day of the next menstrual cycle, to
treat the ovarian cyst (a diameter of 6 cm at US on the
left ovary). Increase of liver enzymes persistently
relapsed after 8 weeks from completion of previous
SHT cycle associated with the ovarian cyst reoccur-
rence on July 2011 (Table 1). A second cycle of alter-
native SHT from October to December 2011, by
Drospirenone (3 mg)/ethinyl estradiol (0.03 mg), was
attempted to gain a prolonged response, again obtain-
ing normalization of liver indices and FOC regression.
However, the patient manifested a new relapse of
FOC and, of more interest, a rapid increase of amino-
transferases and cholestatic indices off therapy, simi-
lar to what happened after the ﬁrst SHT interruption
(Table 2). In prevision of future SHT cycles to treat
recurrent FOC, she received a complete thrombophilic
risk status survey, which resulted absent. Further-
more, the patient underwent a hysteroscopic poly-
pectomy on November 2012. During the next SHT
cycles (January–March and December 2013–May
2014), she reshowed analogous clinical and biochemi-
cal features, as at the ﬁrst referral (Table 2). Particu-
larly, in coincidence of every cycle of SHT, the patient
needed about 8 weeks to normalize liver indices and
4–8 weeks for regression of FOC. On the other hand,
she always experienced hepatic biochemical abnor-
malities and FOC relapse, respectively, after 4 to
8 weeks and 6 to 8 months off-SHT. FOC had diame-
ter varying from 5 to 7.5 cm, singly occurring at both
the ovaries. She was never pregnant.
Table 1 Laboratory and instrumental data throughout the SHT (the initial approach)
Chlormadinone acetate (2 mg)/Ethinyl estradiol (0.03 mg)†
Basal After 4 weeks
on therapy
After 8 weeks
on therapy
Up to the end
of therapy
4–8 weeks
off therapy
6–8 months
off therapy
GGT 6.6 × unl 1.6 × unl inr inr 6.7 × unl 6.4 × unl
ALP 1.9 × unl 1.1 × unl inr inr 2.2 × unl 2.1 × unl
Bilirubin total/conjugated 1.46/0.40 inr inr inr 1.55/0.46 1.5/0.44
AST 1.1 × unl inr inr inr 1.2 × unl 1.2 × unl
ALT 1.6 × unl inr inr inr 1.3 × unl 1.6 × unl
FOC (diameter) 6 cm np np np np 6.5 cm
†Overall treatment from November 2009 to December 2010 for 21 day/month cycle. and ALP, alkaline phosphatase; ALT, alanine amino-
transferase; AST, aspartate aminotransferase; FOC, functional ovarian cyst, detected at ultrasonography; GGT, gamma glutamyl transpep-
tidase; inr, in normal range; np, not present; unl, upper normal limit.
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In recent years, until 2018, she has continued to
take SHT to keep long-suppressed the recurrence of
the FOC, also on the advice of the gynecologist;
throughout the hormonal treatment liver indices per-
sisted normal. As conﬁrmative investigation, at the
time of the enzyme elevation, the total bile acid levels
resulted to be increased, i.e., 10 μmol/L (n.v. < 6).
Finally, acoustic radiation force impulse (ARFI) imag-
ing, a new and promising ultrasound-based diagnos-
tic technique evaluating the wave propagation speed,
allows the assessment of the tissue stiffness. Recently,
ARFI revealed a signiﬁcant liver ﬁbrosis (F2). The
patient provided informed written consent authoriz-
ing use and disclosure of her health information.
Discussion
First of all, we would like to offer readers available lit-
erature data, although not recent and concerning a
similar condition, i.e., an induced hormone hypersti-
mulation, such as that appearing during OHSS.
Nawroth et al.5 described a case of icterus during a
severe OHSS; a 33-year-old woman developed an ami-
notransferases increase, without cholestatic damage,
after 7 days from stimulation with human chorionic
gonadotrophin (HCG) to induce ovulation; no dilata-
tion of bile ducts on liver US imaging was observed
and hepatic laboratory abnormalities resolved after
6 days from normalization of blood levels of HCG.
Obrutz et al.6 detailed a severe liver injury during
OHSS; a 32-year-old patient developed a 100-fold-
increase of aminotransferases levels, ascites, pleural
and pericardial effusion. Similar features were
observed in a 26-year-old woman who manifested
OHSS, presenting with massive ascites, pain at upper
abdomen and dark urine; laboratory data showed
increase of aspartate aminotransferase (AST) and ALT,
and serum estradiol concentration was much higher
than normal values during the early stages of preg-
nancy.7 Borgaonkar and Marshall8 reported a marked
increase of aminotransferases in association with
OHSS: after 23 days from induction of ovulation, their
patient developed ascites and pleural effusion; amino-
transferases reached values of ALT 1472 IU/L and
AST 908 IU/L 4 days following stimulation; ALP and
GGT reached 186 and 908 IU/L, respectively, while
serum bilirubin was normal. Ryley et al.9 described a
patient suffering from severe OHSS, who showed a
sustained increase of aminotransferases persisting at
high levels for a period of 2 months; enzymatic abnor-
malities were associated with several histologic (zonal
fatty degeneration and inﬂammation) and cytological
(mitochondrial crystalline inclusions and dilated endo-
plasmic reticulum) alterations. An observational pro-
spective study, conducted on 50 women with severe
OHSS, evidenced an increase of aminotransferases
from mild to moderate in a third of the population. In
these latter patients, there was also an increase of cho-
lestatic indices. All liver alterations resolved after the
ovarian syndrome recovery.10 Indeed, the only
reported data addressing an eventual link between
liver and ovarian cysts focus on insulin resistance, key
mechanism of nonalcoholic fatty liver disease and
common feature among women with polycystic ovary
syndrome (PCOS), especially in those patients with
hyperandrogenism and chronic anovulation; particu-
larly, PCOS women are at risk for developing meta-
bolic syndrome, impaired glucose tolerance and type
II diabetes mellitus.11
Table 2 Laboratory and instrumental data throughout the SHT (the stable approach)
Drospirenone (3 mg)/Ethinyl estradiol (0.03 mg)†
Basal After 4 weeks
on therapy
After 8 weeks
on therapy
Up to the end
of therapy
4–8 weeks
off therapy
6–8 months
off therapy
GGT 5.8 × unl 1.5 × unl inr inr 6.4 × unl 7.2 × unl
ALP 1.6 × unl 1.3 × unl inr inr 2.1 × unl 1.7 × unl
Bilirubin total/
conjugated
1.5/0.45 inr inr inr 1.58/0.45 1.54/0.44
AST 1.2 × unl inr inr inr 1.2 × unl 1.4 × unl
ALT 1.6 × unl inr inr inr 1.35 × unl 1.5 × unl
FOC (diameter) 7.5 cm np np np np 7 cm
†First cycle, from October 2011 to December 2011; second cycle, from January 2013 to March 2013; third cycle, from December 2013 to
May 2014; fourth cycle, from December 2014 up to today. All cycles were administered for a 21 day/month cycle. The off-therapy results
were a mean value of those registered during the breaks among the several cycles. and ALP, alkaline phosphatase; ALT, alanine amino-
transferase; AST, aspartate aminotransferase; FOC, functional ovarian cyst, detected at ultrasonography; GGT, gamma glutamyl transpep-
tidase; inr, in normal range; np, not present; unl, upper normal limit.
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According to our case, several evidences documen-
ted possible alterations of liver enzymes because of an
unopposed ovarian hormonal overproduction.
Hepatic alterations included a very wide spectrum of
severity varying from mild–moderate forms10 to more
severe ones.5–9 According to Delvigne and Rozenberg,
oestrogens probably cause microvascular alterations
such as vasodilatation, increased vascular permeabil-
ity and consequent hepatocyte swelling, to which fol-
lows an ampliﬁed cellular permeability with
consequent release of AST and ALT; alternatively, the
estrogen-induced production of mediators such as IL-
6 may cause microvascular thromboses and hepatic
ischemia.3 Chen et al.12 highlighted that oestrogens
can hamper transport of bile acids from hepatocyte to
biliary canaliculi because of inhibition of transporters
such as the bile salt export pump and multidrug
resistance-associated transporter 2; in addition, they
inhibit uptake of bile acids by counteracting cotran-
sport systems, sited in the basolateral membrane of
hepatocyte, such as Na+ −taurocholate co-
transporting polypeptide and Na+ −independent
organic anion-transporting polypeptides.12 Surpris-
ingly, in our patient, SHT normalized liver biochemi-
cal alterations in contrast to what commonly
observed.4 So, we think that in this patient a low-dose
of SHT therapy could act on the hypothalamus-pitui-
tary-ovary axis and counteract a probable endoge-
nous ovarian hormonal overproduction. Finally, our
patient developed an endometrial polypus. FOC and
endometrial polypus were signs of the probable unop-
posed estrogenic stimulation.
SHT may play a hepatic protective role in other set-
tings different from ovarian hyperfunction. Callejon
et al.13 reported a selective reduction of cholestasis
indices and follicle-stimulating hormone, without
aminotransferases variation, in a population of
30 postmenopausal women; of note, these patients
assumed transdermal estradiol, which could reduce
the effect of ﬁrst hepatic passage. On the contrary,
Perry and Wiseman14 found that a hormonal therapy
produced only a modest and not signiﬁcant improve-
ment of aminotransferases levels in a wider popula-
tion of postmenopausal women.
On the other hand, oestrogens can act as important
promoter of cell growth and differentiation on speciﬁc
alfa- and beta-receptors; as far as the liver is con-
cerned, the cholangiocytes express both alfa- and
beta-subtypes, while hepatocytes only the alfa-ones;
thus, oestrogens induce cholangiocyte proliferation by
synergistically acting through both genomic and
nongenomic pathways and an estrogenic deﬁciency
could occur in the terminal, ductopenic stage of cho-
langiopathies, as basis for the inefﬁcacy of cholangio-
cyte proliferation to balance the loss of intrahepatic
bile ducts.15
Finally, both SHT combinations were similarly
effective and the choice of continuing the SHT by
using different progestin, i.e., drospirenone, was
made, in agreement with gynecologist, on the basis
of shorter half-life, presence of antiandrogenic
activity and absence of glucocorticoid activity,
characteristics potentially less ‘dangerous’ in the
long-term administration, as conﬁrmed by follow-
ing research.16
As limitation to this study, we should stress that
liver biopsy was not reperformed due to ethical
issues. Hormone proﬁle was not checked, having the
patient not accepted stopping the therapy according
to the gynecological advice. In this setting, we would
like to further stress the patient’s satisfaction and
compliance, which led to a good quality of life.
In conclusion, we hypothesize that the favorable
effect of the ‘low-dose’ SHT to obtaining a stable
recovery of this unexplained long-lasting cholestatic
syndrome is likely due to downregulation of an endog-
enous ovarian overproduction, although estrogen-
regulated local intracellular transduction pathways
cannot be excluded.
Further mechanistic studies are needed to better
clarify the exact role of oestrogens in liver metabolism
and their role in developing new therapeutic
modalities.
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